Ocugen plans Phase I/II trials for macular disease gene therapies

临床2期疫苗基因疗法细胞疗法临床1期
Ocugen plans Phase I/II trials for macular disease gene therapies
Preview
来源: Pharmaceutical Technology
Phalguni Deswal
@Phalguni_GD
Ocugen plans Phase I/II trials for macular disease gene therapies
Preview
来源: Pharmaceutical Technology
Ocugen announced that the manufacturing facility for its regenerative cell therapy for cartilage, NeoCart, is expected for completion by the end of 2023. Image Credit: Sergey Nivens / Shutterstock.
Ocugen plans Phase I/II trials for macular disease gene therapies
Preview
来源: Pharmaceutical Technology
Phase I/II trials for OcugenOcugen’s gene therapies, OCU410 and OCU410ST, are planned for initiation by the end of 2023 in geographic atrophy and Stargardt disease.
The plans follow the US Food and Drug Administration’s (FDA) approval of the Investigational New Drug (IND) application for the two gene therapies.
Recommended Reports
Ocugen plans Phase I/II trials for macular disease gene therapies
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Gene Therapy To Target Bcma and Cd19 in Waldenstrom Macroglobulinemia (Lymph... GlobalData
Ocugen plans Phase I/II trials for macular disease gene therapies
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Gene Therapy to Target BCMA and CS1 for Relapsed and Refractory Multiple Mye... GlobalData
View allCompanies IntelligenceOcugen IncView all
Ocugen is also planning for a Phase III trial in retinitis pigmentosa for OCU400 in Q4 2023/Q1 2024. The Phase III trial initiation is contingent on the FDA’s approval of trial plans and Phase I/II data.
OCU410 is an adeno-associated virus containing a gene that encodes human retinoic acid receptor (RAR)-related orphan receptor alpha (RORα). It is planned to be investigated in geographic atrophy, which is the chronic degeneration of the macula during the late stages of age-related macular degeneration.
OCU410ST was granted the orphan drug designation by the FDA for the treatment of Stargardt disease. Also known as ABCA4 retinopathy, the illness is a rare genetic disorder caused by pathogenic variations in the ABCA4 gene leading to fatty build-up on the macula and loss of vision.
OCU400 is an adeno-associated virus serotype 5 capsid containing the gene for human nuclear hormone receptor NR2E3. It is being developed in partnership with China-based CanSinoBIO. It is currently being evaluated in an open-label Phase II trial (NCT05203939).
An open-label Phase I trial (NCT05802329) for OCU200 in patients with diabetic macular oedema was initiated in Q2 2023. One of the cohorts in the trial will evaluate the combination therapy of OCU200 and NovartisLucentis (ranibizumab).
Ocugen announced that the manufacturing facility for its regenerative cell therapy for cartilage, NeoCart, is expected for completion by the end of 2023, with a Phase III trial for the therapy planned for initiation in H2 2024.
The US-based company is looking for government funding for its inhaled mucosal vaccine platform, with the IND application for the treatment expected to be filled in 2024.
As part of their second quarter financials, Ocugen reported cash equivalents of $70.6m on 30 June 2023. The company also reported a loss of $0.10 per common share in Q2 2023.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.By Cytiva Thematic
Ocugen plans Phase I/II trials for macular disease gene therapies
Preview
来源: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。